S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
The Day of Financial Reckoning Is Near (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
The Day of Financial Reckoning Is Near (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
The Day of Financial Reckoning Is Near (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
S&P 500   4,283.74
DOW   33,999.04
QQQ   329.28
Why Micron Stock Could Be About To Breakout 
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
US to hold trade talks with Taiwan, island drills military
BJ’s Wholesale Club Pops, Will Costco Be Next?
Our Most Important Forecast in 50 Years Tectonic changes are on the way. (Ad)
Why Blue-Chip Tech Like Cisco Systems Is Rebounding
Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
The Day of Financial Reckoning Is Near (Ad)
Trump Organization CFO pleads guilty in tax evasion case
Gas-powered muscle cars drive into the sunset, turn electric
NASDAQ:DFFN

Diffusion Pharmaceuticals - DFFN Stock Forecast, Price & News

$6.92
-0.20 (-2.81%)
(As of 08/18/2022 12:00 AM ET)
Add
Compare
Today's Range
$6.78
$7.03
50-Day Range
$6.45
$8.38
52-Week Range
$5.10
$31.50
Volume
4,872 shs
Average Volume
48,382 shs
Market Capitalization
$14.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.50

Diffusion Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
37.3% Upside
$9.50 Price Target
Short Interest
Healthy
0.88% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.64mentions of Diffusion Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($7.82) to ($6.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

334th out of 1,119 stocks

Pharmaceutical Preparations Industry

154th out of 549 stocks

DFFN stock logo

About Diffusion Pharmaceuticals (NASDAQ:DFFN) Stock

Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 and is based in Charlottesville, Virginia.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. StockNews.com raised Diffusion Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday. HC Wainwright upgraded shares of Diffusion Pharmaceuticals from a "neutral" rating to a "buy" rating and set a $9.50 price objective on the stock in a report on Tuesday.

Diffusion Pharmaceuticals Stock Down 2.8 %

DFFN Stock traded down $0.20 during mid-day trading on Thursday, reaching $6.92. 4,872 shares of the company traded hands, compared to its average volume of 48,382. The stock has a market cap of $14.11 million, a price-to-earnings ratio of -0.56 and a beta of 1.59. Diffusion Pharmaceuticals has a fifty-two week low of $5.10 and a fifty-two week high of $31.50. The firm's 50 day moving average price is $7.31 and its 200 day moving average price is $12.38.

Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DFFN Stock News Headlines

DFFN: Phase 2 GBM Trial to Initiate 2H22…
Diffusion Pharmaceuticals GAAP EPS of -$2.22
5 Stocks Halted In Tuesday's Session
Why Diffusion Pharmaceuticals Shares Are Falling
See More Headlines
Receive DFFN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Diffusion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DFFN Company Calendar

Last Earnings
11/10/2021
Today
8/18/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DFFN
Employees
16
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$9.50
High Stock Price Forecast
$9.50
Low Stock Price Forecast
$9.50
Forecasted Upside/Downside
+37.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-24,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$13.08 per share

Miscellaneous

Free Float
2,002,000
Market Cap
$14.11 million
Optionable
Not Optionable
Beta
1.59

Key Executives

  • Dr. Robert J. Cobuzzi Jr. (Age 57)
    Ph.D., Pres, CEO & Director
    Comp: $1.23M
  • Mr. William Karl Hornung (Age 53)
    Chief Financial Officer
    Comp: $450.68k
  • Mr. William Robert Elder J.D. (Age 39)
    Gen. Counsel & Corp. Sec.
    Comp: $338.36k
  • Dr. Christopher D. Galloway M.D. (Age 51)
    Chief Medical Officer
    Comp: $539.59k
  • Dr. David Randolph Jones M.D. (Age 59)
    Sr. Medical Advisor
  • Ms. Suzanne Cassidy
    Sr. Director & Head of Quality Assurance
  • Dr. Jennifer Llewelyn Ph.D.
    Sr. Director & Head of CMC
  • Ms. Raven Jaeger M.S. (Age 44)
    Chief Regulatory Officer
  • Ms. Kelly Hoy
    Director of Project Management
  • Mr. Harry Cook
    VP of Clinical Operations













DFFN Stock - Frequently Asked Questions

Should I buy or sell Diffusion Pharmaceuticals stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Diffusion Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" DFFN shares.
View DFFN analyst ratings
or view top-rated stocks.

What is Diffusion Pharmaceuticals' stock price forecast for 2022?

1 Wall Street research analysts have issued twelve-month target prices for Diffusion Pharmaceuticals' shares. Their DFFN share price forecasts range from $9.50 to $9.50. On average, they expect the company's share price to reach $9.50 in the next twelve months. This suggests a possible upside of 37.3% from the stock's current price.
View analysts price targets for DFFN
or view top-rated stocks among Wall Street analysts.

How have DFFN shares performed in 2022?

Diffusion Pharmaceuticals' stock was trading at $15.25 at the beginning of 2022. Since then, DFFN stock has decreased by 54.6% and is now trading at $6.9199.
View the best growth stocks for 2022 here
.

When is Diffusion Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our DFFN earnings forecast
.

How were Diffusion Pharmaceuticals' earnings last quarter?

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) issued its earnings results on Wednesday, November, 10th. The company reported ($6.00) earnings per share for the quarter, missing analysts' consensus estimates of ($2.00) by $4.00.

When did Diffusion Pharmaceuticals' stock split?

Diffusion Pharmaceuticals's stock reverse split on the morning of Tuesday, April 19th 2022. The 1-50 reverse split was announced on Tuesday, April 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of Diffusion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Diffusion Pharmaceuticals investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), ADMA Biologics (ADMA), Novan (NOVN), Zosano Pharma (ZSAN), Gran Tierra Energy (GTE), Cogent Biosciences (UMRX), Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE) and Enerplus (ERF).

What is Diffusion Pharmaceuticals' stock symbol?

Diffusion Pharmaceuticals trades on the NASDAQ under the ticker symbol "DFFN."

Who are Diffusion Pharmaceuticals' major shareholders?

Diffusion Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Renaissance Technologies LLC (2.39%) and Trexquant Investment LP (0.52%). Insiders that own company stock include Jane H Hollingsworth, Robert Joseph Jr Cobuzzi and William Robert Elder.
View institutional ownership trends
.

How do I buy shares of Diffusion Pharmaceuticals?

Shares of DFFN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Diffusion Pharmaceuticals' stock price today?

One share of DFFN stock can currently be purchased for approximately $6.92.

How much money does Diffusion Pharmaceuticals make?

Diffusion Pharmaceuticals (NASDAQ:DFFN) has a market capitalization of $14.11 million. The company earns $-24,100,000.00 in net income (profit) each year or ($12.28) on an earnings per share basis.

How can I contact Diffusion Pharmaceuticals?

Diffusion Pharmaceuticals' mailing address is 1317 CARLTON AVENUE SUITE 200, CHARLOTTESVILLE VA, 22902. The official website for the company is www.diffusionpharma.com. The company can be reached via phone at (434) 220-0718, via email at investorrealtions@diffusionpharma.com, or via fax at 434-220-0722.

This page (NASDAQ:DFFN) was last updated on 8/19/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.